Escherichia coli and Klebsiella pneumoniae are major hospital-acquired pathogens, posing severe threats to critically ill and immunocompromised patients. Their pathogenicity and virulence factors easily cause invasive infections, endangering patient health and life. This study developed a dual recombinase polymerase amplification combined with Clustered Regularly Interspaced Short Palindromic Repeats-Cas12a assay for rapid, simultaneous, specific detection of E. coli uidA and K. pneumoniae rcsA genes. The assay operated at 37°C, and the total reaction time was approximately 70 min. The analytical sensitivity for E. coli and K. pneumoniae was 5.37 × 10¹ copies/μL and 5.90 × 10¹ copies/μL, respectively. It showed excellent specificity (no cross-reactivity) and 100% concordance with PCR results in clinical sample validation. This assay overcame limitations of traditional methods, such as bacterial culture (time-consuming) and PCR (the dependency on expensive thermal cyclers), and offers advantages of rapidity, high sensitivity, simplicity, and cost-effectiveness, providing a powerful tool for rapid, accurate clinical diagnosis of E. coli and K. pneumoniae infections. IMPORTANCE: Escherichia coli and Klebsiella pneumoniae are the main pathogens causing hospital-acquired infections, which can lead to serious complications and pose a significant challenge to public health. Therefore, establishing rapid, sensitive, specific, and reliable detection methods for E. coli and K. pneumoniae is of great significance for promoting accurate early clinical diagnosis and guiding treatment decisions. With the increasing incidence of mixed infections, single-target nucleic acid testing can no longer meet clinical needs. In this study, the efficient recombinase polymerase amplification (RPA) isothermal amplification technique was combined with the highly sensitive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas12a detection system to successfully develop a duplex RPA-CRISPR-Cas12a method. This system can specifically and simultaneously identify E. coli (targeting the uidA gene) and K. pneumoniae (targeting the rcsA gene) in a single detection process.
Ischemic stroke remains a primary contributor to global disability and mortality, primarily resulting from interruptions in cerebral blood flow that trigger brain tissue necrosis. Among the various mechanisms of cell death, ferroptosis assumes a key role in the pathophysiology of cerebral infarction. Hypoxia-inducible factors (HIFs) are central to cellular adaptation under hypoxic conditions and exhibits dual regulatory roles in neuronal ferroptosis. This review delineates the intricate mechanisms by which HIF-1α and the less-characterized HIF-3α modulate ferroptosis in ischemic stroke. We detail how HIF-1α promotes ferroptosis by disrupting iron homeostasis, amplifying lipid peroxidation, and activating inflammatory networks, while also highlighting its context-dependent protective functions. Furthermore, we explore the emerging role of HIF-3α, particularly its mitochondrial localization and diverse functions conferred by alternative splicing variants, which may oppose HIF-1α-driven ferroptosis. By synthesizing the distinct regulatory networks of HIF-1α and HIF-3α, this review underscores their potential as therapeutic targets and proposes that selective modulation of these pathways could offer novel neuroprotective strategies for ischemic stroke.
Background and objective: Ischemic stroke (IS) is a leading global cause of disability and mortality, characterized by cerebral hypoxia and tissue necrosis. GTP cyclohydrolase 1 (GCH1) regulates endothelial function and oxidative stress; however, whether circulating GCH1 concentrations are altered in acute ischemic stroke (AIS) remains unclear. This exploratory case–control study aimed to investigate plasma GCH1 levels and their associations with clinical characteristics in patients with AIS. Methods: Seventy-one patients with AIS and 92 controls undergoing routine health examinations were recruited at the Affiliated Hospital of Youjiang Medical University for Nationalities (January 2024–May 2025). Clinical and biochemical data including lipid profiles, C-reactive protein, homocysteine, and National Institutes of Health Stroke Scale (NIHSS) scores (only for patients with AIS) were collected. Plasma GCH1 levels were measured using an enzyme-linked immunosorbent assay. Statistical analyses were performed to evaluate differences between groups and to examine the associations between plasma GCH1 levels and clinical characteristics. Receiver operating characteristic curve analysis was conducted to assess the discriminatory performance of circulating GCH1. Results: Plasma GCH1 concentrations were significantly lower in AIS patients (6.51 ± 3.59 ng/mL vs. 14.32 ± 3.29 ng/mL, p < 0.001). Binary logistic regression analysis showed that lower plasma GCH1 levels were independently associated with AIS (OR = 0.496, 95% CI: 0.385–0.644, p < 0.001), while multiple linear regression analysis demonstrated that AIS was independently associated with lower plasma GCH1 levels ( B = −7.687, 95% CI: −9.011 to −6.362, p < 0.001). Plasma GCH1 showed strong discrimination between the two groups (AUC = 0.924, 95% CI: 0.871–0.978) but was not associated with NIHSS scores (Spearman’s rho = −0.034, p = 0.778). Conclusion: Plasma GCH1 concentrations were lower in patients with AIS than in health-examination controls and showed high apparent discrimination in this dataset. Because GCH1 was measured after stroke onset and the sample-derived threshold was derived in the same case–control sample, these findings do not establish temporality, causality, or clinical diagnostic utility. Prospective multicenter studies including clinically relevant disease controls and independent external validation are required.